Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. (Q30384542)

16 October 2017

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. (English)

1 reference

16 October 2017

1 reference

Brinton Seashore-Ludlow

1

object named as

Brinton Seashore-Ludlow

0 references

Joshua A Bittker

21

object named as

Joshua A Bittker

1 reference

16 October 2017

26

Stuart L Schreiber

1 reference

16 October 2017

Matthew G Rees

2

1 reference

16 October 2017

Jaime H Cheah

3

1 reference

16 October 2017

Murat Cokol

4

1 reference

16 October 2017

Edmund V Price

5

1 reference

16 October 2017

Matthew E Coletti

6

1 reference

16 October 2017

Victor Jones

7

1 reference

16 October 2017

Nicole E Bodycombe

8

1 reference

16 October 2017

Christian K Soule

9

1 reference

16 October 2017

Joshua Gould

10

1 reference

16 October 2017

Benjamin Alexander

11

1 reference

16 October 2017

Ava Li

12

1 reference

16 October 2017

Philip Montgomery

13

1 reference

16 October 2017

Mathias J Wawer

14

1 reference

16 October 2017

Nurdan Kuru

15

1 reference

16 October 2017

Joanne D Kotz

16

1 reference

16 October 2017

C Suk-Yee Hon

17

1 reference

16 October 2017

Benito Munoz

18

1 reference

16 October 2017

Ted Liefeld

19

1 reference

16 October 2017

Vlado Dančík

20

1 reference

16 October 2017

Michelle Palmer

22

1 reference

16 October 2017

James E Bradner

23

1 reference

16 October 2017

Alykhan F Shamji

24

1 reference

16 October 2017

Paul A Clemons

25

1 reference

16 October 2017

19 October 2015

1 reference

16 October 2017

1 reference

16 October 2017

5

1 reference

16 October 2017

11

1 reference

16 October 2017

1210-1223

1 reference

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Emergence of new ALK mutations at relapse of neuroblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

NAMPT is the cellular target of STF-31-like small-molecule probes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Automated Structure-Activity Relationship Mining: Connecting Chemical Structure to Biological Profiles

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Inconsistency in large pharmacogenomic studies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Cancer drug resistance: an evolving paradigm

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Combinatorial drug therapy for cancer in the post-genomic era.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Circumventing cancer drug resistance in the era of personalized medicine

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Systematic identification of genomic markers of drug sensitivity in cancer cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Comprehensive analysis of kinase inhibitor selectivity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Nakiterpiosin targets tubulin and triggers mitotic catastrophe in human cancer cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

CLEAN: CLustering Enrichment ANalysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Activating mutations in ALK provide a therapeutic target in neuroblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

The NCI60 human tumour cell line anticancer drug screen

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

The search for synergy: a critical review from a response surface perspective.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

ALK amplification and protein expression predict inferior prognosis in neuroblastomas.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631646

Precision Oncology: An Overview

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26482930

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/2159-8290.CD-15-0235

1 reference

16 October 2017

1 reference

16 October 2017

PubMed publication ID

26482930

1 reference